miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we ident...

Full description

Bibliographic Details
Main Authors: Guoshu Bi, Jiaqi Liang, Mengnan Zhao, Huan Zhang, Xing Jin, Tao Lu, Yuansheng Zheng, Yunyi Bian, Zhencong Chen, Yiwei Huang, Valeria Besskaya, Cheng Zhan, Qun Wang, Lijie Tan
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: Non-coding RNAs
miRNA
cisplatin
pemetrexed
chemoresistance
CRISPR-Cas9
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253122000695

Internet

http://www.sciencedirect.com/science/article/pii/S2162253122000695

Similar Items